2026年欧洲肿瘤内科学会（ESMO）年会将于10月下旬举行，刚刚，大会官网陆续公布了部分最新突破（LBA）摘要及口头报告摘要。本文整理了妇瘤领域的共8项LBA摘要+10项口头报告摘要研究，涵盖卵巢癌、子宫内膜癌及宫颈癌三大瘤种。8项LBA研究中，中国学者牵头的研究共3项，分别涉及HER2 ADC皮下固定复方制剂、Nectin-4 ADC及PD-1/CTLA-4双抗。现将各专场摘要按摘要号、英文标题、中文标题及讲者整理如下，供临床医生会前参考。具体研究数据以大会现场报告及最终发表版摘要为准。
编者按：2026年欧洲肿瘤内科学会（ESMO）年会将于10月下旬举行，刚刚，大会官网陆续公布了部分最新突破（LBA）摘要及口头报告摘要。本文整理了妇瘤领域的共8项LBA摘要+10项口头报告摘要研究，涵盖卵巢癌、子宫内膜癌及宫颈癌三大瘤种。8项LBA研究中，中国学者牵头的研究共3项，分别涉及HER2 ADC皮下固定复方制剂、Nectin-4 ADC及PD-1/CTLA-4双抗。现将各专场摘要按摘要号、英文标题、中文标题及讲者整理如下，供临床医生会前参考。具体研究数据以大会现场报告及最终发表版摘要为准。
总统研讨会III
10月26日 16:30–18:15
Alicante Auditorium–Hall 6
1.摘要号：LBA11
英文标题：Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study
中文标题：Sacituzumab Tirumotecan治疗既往经治晚期或复发性子宫内膜癌：III期TroFuse-005/ENGOT-en23/GOG-3095研究结果
讲者：Domenica Lorusso (Pieve Emanuele, Italy)
2.摘要号：LBA12
英文标题：KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-Line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC)
中文标题：KEYNOTE-C93/GOG-3064/ENGOT-en15：帕博利珠单抗（Pembro）对比卡铂（C）联合紫杉醇（P）一线治疗错配修复缺陷（dMMR）晚期或复发性子宫内膜癌（a/rEC）的III期随机开放标签研究
讲者：Brian M. Slomovitz (Miami Beach, United States of America)
优选口头报告专场：妇科肿瘤
10月24日 14:45–16:15
Barcelona Auditorium–Hall 9
1.摘要号：1239O
英文标题：NRG-GY020: Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk (HIR) Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
中文标题：NRG-GY020：放疗±MK-3475（帕博利珠单抗）治疗新诊断早期高中危（HIR）错配修复缺陷（dMMR）子宫内膜样癌的III期随机研究
讲者：Floor Backes (Columbus, United States of America)
2.摘要号：LBA36
英文标题：Clinical Utility of Circulating Tumor DNA (ctDNA) for Participants With Resected, High-Risk dMMR Endometrial Cancer (EC) Receiving Adjuvant Treatment: Results From the ENGOT-en11/GOG-3053/KEYNOTE-B21 Study
中文标题：循环肿瘤DNA（ctDNA）在接受辅助治疗的切除后高危dMMR子宫内膜癌（EC）患者中的临床价值：ENGOT-en11/GOG-3053/KEYNOTE-B21研究结果
讲者：Floor Backes (Columbus, United States of America)
3.摘要号：LBA37
英文标题：Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study
中文标题：度伐利尤单抗（D）联合卡铂/紫杉醇（CP）后D±奥拉帕利（O）治疗晚期/复发性子宫内膜癌（a/rEC）：随机III期DUO-E/GOG-3041/ENGOT-EN10研究总生存（OS）中期分析与安全性
讲者：Shannon N. Westin (Houston, United States of America)
4.摘要号：LBA38
英文标题：Final overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)
中文标题：BEATcc（ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030）最终总生存（OS）结果：阿替利珠单抗（atezo）联合化疗（CT）与贝伐珠单抗（bev）一线治疗转移性、持续性或复发性宫颈癌（R/M CC）的随机III期研究
讲者：Ana Oaknin (Majadahonda, Spain)
5.摘要号：1240O
英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial
中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合化疗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌（R/M CC）：一项双盲、随机、安慰剂对照III期研究结果
讲者：刘继红教授 （中山大学肿瘤防治中心）
快速口头报告 1
10月24日 08:30–10:00
Murcia Auditorium – Hall 3
1.摘要号：LBA39
英文标题：First results from the randomised ENGOT-OV56/NSGO-CTU-DOVACC trial investigating olaparib (ola), durvalumab (durva) and UV1 vaccination as maintenance therapy for patients (pts) with BRCA-wildtype (wt) recurrent ovarian cancer (ROC)
中文标题：ENGOT-OV56/NSGO-CTU-DOVACC随机研究首次结果：奥拉帕利（ola）联合度伐利尤单抗（durva）及UV1疫苗作为BRCA野生型（wt）复发性卵巢癌（ROC）患者维持治疗
讲者：Trine Jakobi Nøttrup (Copenhagen, Denmark)
2.摘要号：1241RO
英文标题：Preliminary Efficacy of INCB123667 (CDK2 Inhibition) with Bevacizumab in Recurrent Epithelial Ovarian Cancer (rEOC)
中文标题：INCB123667（CDK2抑制剂）联合贝伐珠单抗治疗复发性上皮性卵巢癌（rEOC）的初步疗效
讲者：Domenica Lorusso (Pieve Emanuele, Italy)
3.摘要号：1242RO
英文标题：Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)
中文标题：Azenosertib治疗铂耐药卵巢癌（PROC）：DENALI研究（GOG-3066）Part 1b 总生存分析
讲者：Fiona Simpkins (Philadelphia, United States of America)
4.摘要号：1243RO
英文标题：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer
中文标题：全球首创皮下注射双表位抗HER2 ADC联合PD-L1抑制剂固定复方制剂JSKN033用于经治宫颈癌的临床研究
讲者：吴小华教授（复旦大学附属肿瘤医院妇瘤科）
5.摘要号：1244RO
英文标题：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study
中文标题：新型Nectin-4靶向抗体药物偶联物SHR-A2102治疗复发/转移性宫颈癌II期临床研究结果
讲者：刘继红教授（中山大学肿瘤防治中心）
快速口头报告2：妇科肿瘤
10月24日 08:30–10:00
Burgos Auditorium - Hall 3
1.摘要号：LBA40
英文标题：Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer (PROC)
中文标题：ZW191在重度经治铂耐药卵巢癌（PROC）患者中的随机剂量优化研究
讲者：Jung-Yun Lee (Seoul, Republic of Korea)
2.摘要号：1245RO
英文标题：Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)
中文标题：FONTANA研究更新：叶酸受体α（FRα）靶向抗体偶联药物（ADC）Torvutatug samrotecan（torvu-sam）治疗铂耐药卵巢癌（PROC）患者
讲者：Funda Meric-Bernstam (Houston, United States of America, TX)
3.摘要号：LBA41
英文标题：Mocertatug rezetecan (Mo-Rez) in patients with platinum-resistant ovarian cancer (PROC): Updated results with longer follow-up from the global BEHOLD-1 study
中文标题：Mocertatug rezetecan（Mo-Rez）治疗铂耐药卵巢癌（PROC）：全球BEHOLD-1研究延长随访更新结果
讲者：Vanda Salutari (Rome, Italy)
4.摘要号：1248RO
英文标题：BEHOLD-1: Exploratory analysis of biomarkers associated with mocertatug rezetecan (Mo-Rez) response in patients with platinum-resistant ovarian cancer (PROC)
中文标题：BEHOLD-1：Mocertatug rezetecan（Mo-Rez）治疗铂耐药卵巢癌（PROC）患者疗效相关生物标志物探索性分析
讲者：Stephanie Lheureux (Toronto, Canada)
5.摘要号：1247RO
英文标题：Raludotatug Deruxtecan (R-DXd) + Bevacizumab (Bev) in Participants (Pts) With Platinum-Resistant Recurrent Ovarian Cancer (PROC): Results for Cohort B-1 of the Phase 1b/2 REJOICE-Ovarian02 Study
中文标题：Raludotatug Deruxtecan（R-DXd）联合贝伐珠单抗（Bev）治疗铂耐药复发性卵巢癌（PROC）：Ib/II期REJOICE-Ovarian02研究B-1队列结果
讲者：Ana Oaknin (Majadahonda, Spain)
6.摘要号：1246RO
英文标题：Efficacy and safety of sofetabart mipitecan (Sofe-M), a folate receptor alpha (FRα) targeting antibody drug conjugate (ADC), plus bevacizumab (bev) in recurrent platinum (plat) sensitive ovarian cancer (PSOC)
中文标题：叶酸受体α（FRα）靶向抗体偶联药物（ADC）Sofetabart mipitecan（Sofe-M）联合贝伐珠单抗（bev）治疗复发性铂敏感卵巢癌（PSOC）的疗效与安全性
讲者：Chrisann Kyi (New York, United States of America)